Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma

Ann Neurol. 1978 May;3(5):441-4. doi: 10.1002/ana.410030515.

Abstract

An unusual neurological syndrome occurred in 4 of 158 patients treated for osteogenic sarcoma with combination chemotherapy. There was an abrupt onset of focal cerebral deficits approximately ten days after chemotherapy with vincristine and high-dose methotrexate plus citrovorum factor rescue. The syndrome was short lived and always occurred early in the course of treatment. Prolonged neurological deficits remained in 2 patients. When similar chemotherapy was reinstituted in the 4 patients, no further neurological complications ensued. Possible causes include a leukoencephalopathy related to methotrexate or an embolic cerebral vasculopathy related to necrotic tumor microemboli emanating from the lungs.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Bone Neoplasms / drug therapy*
  • Brain Diseases / chemically induced
  • Brain Diseases / etiology*
  • Drug Therapy, Combination
  • Female
  • Femoral Neoplasms / drug therapy
  • Humans
  • Humerus
  • Leucovorin / administration & dosage
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / adverse effects*
  • Neoplasm Metastasis
  • Osteosarcoma / drug therapy*
  • Pelvic Bones
  • Syndrome
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Leucovorin
  • Methotrexate